Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORMP Oramed Pharmaceuticals

Market Closed 03-28 16:00:00 EDT

2.21

-0.09

-3.91%

盘后2.22

+0.01+0.45%

19:05 EDT

High2.32	Low2.18	Vol76.38K
Open2.32	D1 Closing2.30	Amplitude5.93%
Mkt Cap89.09M	Tradable Cap70.72M	Total Shares40.31M
T/O170.33K	T/O Rate0.24%	Tradable Shares32.00M
P/B0.61	ROE-12.39%	EPS0.11
52wk High3.09	52wk Low1.96	P/E20.19
Dividend0.00	Div.Yield0.00	ROA-4.25%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ORMP","market":"US","secType":"STK","nameCN":"Oramed Pharmaceuticals","latestPrice":2.21,"timestamp":1743192000000,"preClose":2.3,"halted":0,"volume":76384,"hourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.21,"latestTime":"19:05 EDT","volume":3203,"amount":7101.367,"timestamp":1743203116207},"delay":0,"floatShares":31998740,"shares":40312069,"eps":0.109458,"marketStatus":"Market Closed","change":-0.09,"latestTime":"03-28 16:00:00 EDT","open":2.32,"high":2.32,"low":2.1835,"amount":170329.712784,"amplitude":0.059348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.109458,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.3,"postHourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.21,"latestTime":"19:05 EDT","volume":3203,"amount":7101.367,"timestamp":1743203116207},"volumeRatio":2.48650707199493,"impliedVol":1.293,"impliedVolPercentile":0.564},"requestUrl":"/m/hq/s/ORMP","defaultTab":"news","newsList":[{"id":"2521254511","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521254511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521254511?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 04:24","pubTimestamp":1742588645,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of2cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q421T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2520688484","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688484","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688484?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:19","pubTimestamp":1742242762,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of2cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL8N3Q01PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2519864857","title":"Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2519864857","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519864857?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 01:05","pubTimestamp":1741885520,"startTime":"0","endTime":"0","summary":"As the United States stock market grapples with volatility, driven by concerns about economic health and shifting investor sentiment, opportunities in lesser-known areas like penny stocks are gaining attention. While the term 'penny stocks' might seem outdated, these investments often represent smaller or newer companies that can offer growth potential at lower price points. When backed by strong financials and sound fundamentals, they provide investors a chance to uncover hidden value amidst broader market fluctuations.Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery, with a market cap of $105.62 million.Overview: Tiziana Life Sciences Ltd is a biotechnology company that develops molecules for treating oncology and immunology diseases in the United States, with a market cap of $149.45 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oramed-pharmaceuticals-2-other-penny-170520527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4209","PHX","BABB","TTI","AVIR","BK4007","BK4563","ORMP","BK4179","TLSA","BK4021","BK4213","SB"],"gpt_icon":0},{"id":"2518788026","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518788026?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:36","pubTimestamp":1741638969,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of2cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT27A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2517297889","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517297889","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517297889?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:02","pubTimestamp":1741208561,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of2cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL5N3PO27G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2516674889","title":"Oramed Pharmaceuticals Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674889","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674889?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc.   , a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms,today issued a letter to its shareholders from its President and Chief Executive Officer Nadav Kidron.Oramed-HTIT Joint Venture: OraTech - A Transformational Partnership. We are excited about our joint venture, OraTech Pharmaceuticals, Inc. , which we believe represents a significant step forward in advancing our proprietary oral drug delivery technology. This company will serve as the foundation for developing, marketing, and commercia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oramed-pharmaceuticals-issues-letter-shareholders-140000157.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oramed-pharmaceuticals-issues-letter-shareholders-140000157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2516038301","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516038301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516038301?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 05:19","pubTimestamp":1740777545,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of2cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ2E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2510367060","title":"Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2510367060","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510367060?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 08:11","pubTimestamp":1739319065,"startTime":"0","endTime":"0","summary":"As Wall Street navigates the complexities of tariffs and Federal Reserve Chair Jerome Powell's testimony, the U.S. stock market remains a mixed bag with indices showing varied performance. Amid these broader economic discussions, penny stocks continue to capture investor interest by offering potential growth opportunities at lower price points. While often associated with smaller or newer companies, these stocks can present compelling prospects when backed by strong financials and solid fundamentals, making them noteworthy candidates for investors seeking hidden gems in today's market landscape.Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery, with a market cap of $87.48 million.Overview: Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics to stimulate the immune system for cancer treatment, with a market cap o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oramed-pharmaceuticals-2-other-us-001105068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BABB","SB","BK4139","BK4007","BK4563","HOWL","BK4021","PVL","ORMP","VSTA","BK4213","BK4209"],"gpt_icon":0},{"id":"2510339931","title":"Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2510339931","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510339931?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 00:10","pubTimestamp":1739290231,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals  said Tuesday that it signed definitive deals to form a joint venture with Hefei Tianhui Biotech that will bring Oramed's oral insulin to market and focus on its protein oral delivery technology.The joint venture, to be named OraTech Pharmaceuticals, is expected to list on Nasdaq, according to Oramed.The deals grant Oramed shareholders the right to receive a majority of Oramed's interest in OraTech, the company said.Oramed also said it will invest $15 million in the joint venture, while Hefei Tianhui Biotech will contribute $60 million. Oramed will also transfer its oral insulin and POD technology, along with other assets, to OraTech, while Hefei Tianhui will supply the oral insulin capsules, the company added.Shares of Oramed Pharmaceuticals were up over 24% in recent Tuesday trading.Price: 2.71, Change: +0.54, Percent Change: +24.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4185","ORMP","JYNT","BK4007"],"gpt_icon":0},{"id":"2510335387","title":"Oramed enters JV for insulin development and commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2510335387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510335387?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:20","pubTimestamp":1739283621,"startTime":"0","endTime":"0","summary":"Oramed (ORMP) has entered into definitive agreements to spin off its Protein Oral Delivery – POD – technology into a newly formed joint venture, Or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oramed-enters-jv-for-insulin-development-and-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oramed-enters-jv-for-insulin-development-and-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2510382364","title":"BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382364","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382364?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:17","pubTimestamp":1739283468,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed Announces Joint Venture To Develop And Commercialize Oral InsulinFeb 11 (Reuters) - Oramed Pharmaceuticals ORMP.O:ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2510823873","title":"Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin","url":"https://stock-news.laohu8.com/highlight/detail?id=2510823873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510823873?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2510823583","title":"Oramed Pharmaceuticals Inc: Oramed Shareholders to Receive Right to a Direct Stake in Oratech, Expected to Go Public on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2510823583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510823583?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2510823333","title":"Oramed Pharmaceuticals Inc: Htit to Invest $60 Mln, Oramed to Invest $15 Mln Into Oratech","url":"https://stock-news.laohu8.com/highlight/detail?id=2510823333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510823333?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2510382382","title":"Oramed Pharmaceuticals Inc - New Phase 3 Trial in U.S. Expected to Begin This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382382?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2510382337","title":"Oramed Pharmaceuticals Inc - Announces Joint Venture With Htit to Form Oratech","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382337?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2510330382","title":"Oramed Pharmaceuticals Inc - Oratech to Receive Royalty Payments From Sales of Oral Insulin in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2510330382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510330382?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA3X8XTP:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2510382283","title":"Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin","url":"https://stock-news.laohu8.com/highlight/detail?id=2510382283","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510382283?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 22:15","pubTimestamp":1739283300,"startTime":"0","endTime":"0","summary":"New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities. Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.OraTech will have global marketing rights to Oramed's POD oral protein delivery technology.HTIT to invest $60 million, Oramed to invest $15 million into OraTech.HTIT to provide a supply agreement for oral insulin capsules.New Phase 3 trial in the U.S. with a revised protocol expected to begin this quarter.OraTech to advance registration of oral insulin in the U.S. and other countries.OraTech to receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted, and commercialization preparations are underway by HTIT.OraTech will leverage HTIT's expertise in capsule production and cost-efficient manufacturing, ensuring a robust, reliable, and sc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oramed-announces-transformative-joint-venture-141500390.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oramed-announces-transformative-joint-venture-141500390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4185","JYNT","ORMP","BK4007","AAQC"],"gpt_icon":0},{"id":"2492916979","title":"BRIEF-Oramed Pharmaceuticals Inc - On Dec 13, Received $13.2 Million Payment From Scilex, Pursuant To Terms Of Tranche A Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2492916979","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492916979?lang=en_us&edition=full_marsco","pubTime":"2024-12-18 06:07","pubTimestamp":1734473262,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Oramed Pharmaceuticals Inc   :   * ORAMED PHARMACEUTICALS INC - ON DEC 13, RECEIVED $13.2 MILLION PAYMENT FROM SCILEX, PURSUANT TO TERMS OF TRANCHE A NOTESource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ON","BK4141","IE00BZ199S13.USD","LU1854103824.USD","LU0724618433.USD","LU0348723411.USD","LU1548497426.USD","LU2357305700.SGD","ORMP","BK4585","LU2298322129.HKD","BK4512","BK4588","LU1720051017.SGD","LU1861220033.SGD","LU1978683503.SGD","LU0124384867.USD","LU2360107325.USD","LU1854104046.USD","LU1720051108.HKD","IE00BD6J9T35.USD","LU1861219969.SGD","LU1861215975.USD","LU1861214812.USD"],"gpt_icon":0},{"id":"2492300916","title":"Oramed Pharmaceuticals Inc - on Dec 13, Received $13.2 Mln Payment From Scilex, Pursuant to Terms of Tranche a Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2492300916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492300916?lang=en_us&edition=full_marsco","pubTime":"2024-12-18 05:59","pubTimestamp":1734472781,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI111:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oramed.com","stockEarnings":[{"period":"1week","weight":-0.0515},{"period":"1month","weight":0.0474},{"period":"3month","weight":-0.0675},{"period":"6month","weight":-0.1089},{"period":"1year","weight":-0.2432},{"period":"ytd","weight":-0.0868}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.004413},{"month":2,"riseRate":0.5,"avgChangeRate":-0.020726},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.010886},{"month":4,"riseRate":0.75,"avgChangeRate":0.011707},{"month":5,"riseRate":0.5,"avgChangeRate":0.044296},{"month":6,"riseRate":0.416667,"avgChangeRate":0.023552},{"month":7,"riseRate":0.5,"avgChangeRate":0.052031},{"month":8,"riseRate":0.333333,"avgChangeRate":0.007097},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.069591},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.023199},{"month":11,"riseRate":0.5,"avgChangeRate":0.132712},{"month":12,"riseRate":0.416667,"avgChangeRate":0.055612}],"exchange":"NASDAQ","name":"Oramed Pharmaceuticals","nameEN":"Oramed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oramed Pharmaceuticals,ORMP,Oramed Pharmaceuticals股票,Oramed Pharmaceuticals股票老虎,Oramed Pharmaceuticals股票老虎国际,Oramed Pharmaceuticals行情,Oramed Pharmaceuticals股票行情,Oramed Pharmaceuticals股价,Oramed Pharmaceuticals股市,Oramed Pharmaceuticals股票价格,Oramed Pharmaceuticals股票交易,Oramed Pharmaceuticals股票购买,Oramed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction